Shamburg News · 8-K filed Oct 26, 2026, 8:50 AM EDT
Azitra Halts ATM Share Sales and Reports Ex Vivo ATR-COSF Skin Study Results
AZTR · Azitra, Inc.
- Other event
- Financing
- Materiality: medium
Azitra, Inc. disclosed that it has decided not to use its at-the-market offering program with A.G.P./Alliance Global Partners for the foreseeable future. From September 28, 2026 through October 26, 2026, the company sold 1,000 shares under the program for aggregate gross proceeds of approximately $126. The company also announced ex vivo study results for its ATR-COSF cosmetic candidate, with first-in-human data anticipated by year end.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001493152-26-048431.
Written from the filing by Shamburg Markets. Figures are as reported by the company.